Efficacy of estriol in inhibiting epithelial proliferation in mammary fibroadenoma: Randomized clinical trial

Sao Paulo Medical Journal

Volumn 125, Issue 6, 2007, Pages 343-350

  Estevão, Rodrigo Augusto Fernandes ^a,b   Baracat, Edmund Chada ^a   Logullo, Ângela Flávia ^a   Oshima, Celina Tizuko Fujiyama ^a   Nazário, Afonso Celso Pinto ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Contraceptives oral; Estriol; Fibroadenoma; Ki 67 antigen; Myc genes

Indexed keywords

ESTRIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; KI 67 ANTIGEN; MYC PROTEIN; ORAL CONTRACEPTIVE AGENT; PLACEBO;

ADULT; ANTIGEN EXPRESSION; ARTICLE; BRAZIL; BREAST EPITHELIUM; BREAST FIBROADENOMA; BREAST SURGERY; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; MULTIPLE CYCLE TREATMENT; PROTEIN ANALYSIS; RANDOMIZED CONTROLLED TRIAL;

EID: 42249097127     PISSN: 15163180     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1516-31802007000600008     Document Type: Article

References (45)

1. Dent DM, Cant PJ, Fibroadenoma, World J Surg. 1989;13(6):706-10.
2. Alle KM, Moss J, Venegas RJ, Khalkhali I, Klein SR. Conservative management of fibroadenoma of the breast. Br J Surg. 1996;83(7):992-3.
3. Greenberg R, Skornick Y, Kaplan O. Management of breast fibroadenomas. J Gen Intern Med 1998;13(9):640-5.
4. Funderburk WW, Rosero E, Leffall LD. Breast lesions in blacks. Surg Gynecol Obstet. 1972;135(1):58-60.
5. Nigdo DM, Organ CH Jr. Fibroadenoma of the female breast. Some epidemiologic surprises. Postgrad Med. 1976;59(5):113-7.
6. Bartow SA, Pathak Dr, Black WC, Key CR, Teaf SR. Prevalence of benign, atypical, and malignant breast lesions in populations at different risk for breast cancer. A forensic autopsy study. Cancer. 1987;60(11):2751-60.
7. Haagensen CD. Diseases of the breast. 3rd ed. Philadelphia: WB Saunders: 1986.
8. Carry NJ, Carter C, Rubin C, Ravichandran D, Royle Gt, Taylor I. Management of fibroadenoma of the breast. Ann R Coll Surg Engl. 1995;77(2):127-30.
9. Wilkinson S, Anderson TJ. Rifkind E, Chetty U, Forrest AP. Fibroadenoma of the breast a follow-up of conservative management. Br J Surg 1989;76(4):390-1.
10. Sitruk-ware LR, Sterkers N, Mowszowich I, Mauvais-Jarvis P, Inadequate corpus luteal function in women with benign breast diseases. J Clin Endocrinol Metab. 1977;44(4):771-4.
11. Monterrosa Castro A. Actualización de conceptos en anticonceptivos orales combinados. [Monograph online] 2nd ed. Colombia; 2000. Available from: http://encolombia.com/anticonceptivosorales.htm. Accessed in 2007 (Oct 8).
12. Borgelt-Hansen L. Oral contraceptive: an update on health benefit and risks. J Am Pharm Assoc (Wash). 2001;41(6):875-6.
13. Ravnihar B, Seigel DG, Lindtner J. An epidemiologic study of breast cancer and benign breast neoplasias in relation to the oral contraceptive and estrogen use. Eur J Cancer. 1997;15(4):395-405.
14. Sitruk-Ware R, Thalabard JC, Benotmane A, Mauvais-Jarvis P. Risk factors for breast fibroadenoma in young women. Contraception. 1989;(3):251-68.
15. Oral-contracetive use and the risk of breast cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med. 1986;15(7):405-11.
16. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med. 2002;346(26):2025-32.
17. Zveibil DK. Avaliação do conteúdo de DNA em carcinomas invasivos da mama por meio análise e imagem: interação de fatores prognósticos citométricos com a avaliação morfológica e imuno-histoquímica. [thesis]. São Paulo: Universidade Federal de São Paulo - Escola Paulisa de Medicina; 1995.
18. Simomoto M, Nazário AC, Gebrim LH, Simões MJ, Baracat EC, de Lima GR. Morphometric Analysis of the Epithelium of Mammary Fibroadenomas During the Proliferative and Secretory Phases of the Menstrual Cycle. Breast J. 1995;5(4):256-61.
19. Hueb AS. Expressão do antígo nuclear de proliferação celular no epitélio do fibroadenoma mamário de mulheres tratadas com contraceptivo hormonal oral combinado. [dissertation]. São Paulo: Universidade Federal de São Paulo - Escola Paulista de Medicina; 2000.
20. Taniguchi CK. Atividade proliferativa do epitélio do fibroadenoma de mulheres tratadas com contraceptivo hormonal oral combinado por quatro ciclos. [dissertation]. São Paulo: Universidade Federal de São Paulo - Escola Paulista de Medicina; 2002.
21. Speroff L, Glass RH, Kase NG. Endocrinologia ginecológica clínica e infertilidade. 7th ed. São Paulo: Manole; 2004.
22. Hall PA, Levison DA. Review: assessment of cell proliferation in histological material. J Clin Pathol.1990;43(3):184-92.
23. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983;31(1):13-20.
24. Sawhney N, Hall Ki-67 - structure, funtion, and new antibodies. J Pathol. 1992;168(2):161-2
25. Bishop JM. Retroviruses and cacncer genes. Adv Cancer Res. 1982;37:1-32.
26. Amati B, Alevizopoulos K, Vlach J. Myc and the cell cycle. Front Biosci. 1998;3:d250-68.
27. Duesberh PH, Bister K, Vogt PK. The RNA of avian acute leukemia virus MC29. Proc Natl Acad Sci U S A. 1977;74(10):4320-4.
28. Neel BG, Jhanwar SC, Chaganti RS, Hayward WS. Two human c-onc genes are located on the long arm of chromosome 8. Proc Natl Acad Sci U S A. 1982;79(24):7842-6.
29. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene. 1999;18(19):3004-16.
30. Prendergast GC. Mechanisms of apoptosis by c-Myc. Oncogene. 1999;18(19):2967-87.
31. Garte SJ. The c-myc oncogene in tumor progression. Crit Rev Oncog. 1993;4(4):435-49.
32. Liao DJ, Dickson RB. c-Myc in breast cancer. Endocr Relat Cancer. 2007;7(3):143-64.
33. Gerdes J, Lemke H, Baish H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133(4):1710-5.
34. Neter J, Wasserman W, Kutner MH: Applied linear statistical models. 3rd ed. New York: Irwin Inc; 1990.
35. Conover WJ, Practical nonparametric statistics. 2nd ed. New York: John & Sons, Inc. 1980.
36. Robbins SL. Cotran RS, Kumar V. Robbins patologia estrutural e functional. 5th ed. Rio de Janeiro: Guanabara Koogan; 1996.
37. Clare SE, Morrow M. Management of the palpable breast mass. In: Harris JR, Lippman ME, Morrow M, Osborne CK, editors. Disease of the breast, Philadelhia: Lippincott Williams & Wilkins; 2000. p. 38-9.
38. Hasebe T, Imoto S, Sasaki S, Tsubono Y, Mukai K. Proliferative activity and rumor angiogenesis is closely correlated to stromal cellularity of fibroadenoma: proposal fibroadenoma, cellular variant. Pathol Int. 199;49(5):435-43.
39. Pasqualini JR, Cortes-Prieto J, Chetrite G, Talbi M, Ruiz A. Concentrations of estrone, estradiol and their sulfates, and evaluation of sulfatase and aromatase activities in patients with breast fibroadenoma. Int J Cancer 1997;70(6):639-43.
40. Umekita Y, Yoshida H. Immunohistochemical study of MIB1 expression in phyllodes tumor and fibroadenoma. Pathol Int. 1999;49(9):807-10.
41. Hardman JG, Limbird LE, Molinoff PB, Ruddou RW, Gilman AG. Goodman and Gilman's: The pharmacological basis of therapeutics. 9th ed. New York: McGrall-Hill; 1996.
42. Kuijper A, Buerger H, Simon R, et al. Analysis of the progression of fibroepithelial tumours of the breast by PCR-based clonality assay. J Pathol. 2002;197(5):575-81.
43. Canny PE, Berkowitz GS, Kelsey JL, LiVolsi VA. Fibroadenoma and the use of exogenous hormones. A case-control study. Am J Epidemiol. 1998;127(3):454-61.
44. Rohan TE, Miller AB. A cohort study of oral contraceptive use and rick aof benign disease. Int J Cancer. 19;2(2):191-6.
45. Yu H, Rohan TE, Cook MG, Howe GR, Miller AB. Risk factors for fibroadenoma: a case-control study in Australia. Am J Epidemiol. 1992;135(3):247-58.